Loading…
Global eye-health company making contact lenses, eye surgery devices and eye-care/pharmaceutical products, spun off from Bausch Health.
Global eye-health company making contact lenses, eye surgery devices and eye-care/pharmaceutical products, spun off from Bausch Health.
Is the same business as the New York line, listed on both exchanges. Contact lenses and eye-health products are repeat purchases, while surgical products, cataract equipment, are sold to clinics and hospitals. Bausch Health remains its controlling shareholder after the 2022 float.
In one line: A dedicated eye-care peer to Alcon/CooperCompanies.
Moat: narrow (brand, scale, regulatory licence). Long-established Bausch + Lomb brand and broad regulatory approvals across contact lens and surgical device lines.
Headquarters: Vaughan, Canada / Bridgewater, New Jersey · Founded: 1853 · Employees: 13,000
Size Bausch + Lomb (BLCO.TO) is a Canada Health Care company (Medical Specialties) with a market value of $7.20B, the 93rd largest of 420 Canada companies the cockpit tracks. Shares closed at C$28.19 on 6 Nov 2026.
Performance Over six months the shares gained 31.1%, against +27.7% for the median peer and +5.2% for the Canada market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 11.3% over the last twelve months (peer median +2.7%); the operating margin is 9.4% (peer median 17.3%).
Valuation It trades at 17.3× forward earnings against a peer median of 21.0× (4th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points below its cost of capital (6.2% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$7.71B | C$7.00B | C$6.89B | C$5.50B | C$5.11B |
| Revenue growth | — | +2% | +25% | +8% | — |
| Gross profit | C$4.50B | C$3.84B | C$3.79B | C$3.00B | C$2.72B |
| EBITDA | C$1.30B | C$836M | C$924M | C$777M | C$812M |
| Net income | -C$158M | -C$494M | -C$456M | -C$345M | C$8.13M |
| Free cash flow | C$359M | -C$90.6M | -C$84.9M | -C$262M | C$230M |
| Capital expenditure | C$422M | C$479M | C$419M | C$240M | C$298M |
| Total debt | C$7.25B | C$7.20B | C$7.10B | C$6.20B | C$3.46B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bausch + Lomb BLCO.TO | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% |
| Alcon ALC.SW | $37.5B | +22% | -1% | 11% | 21.4× | 12.9% |
| Cooper Companies (The) COO | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| Carl Zeiss Meditec AFX.DE | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% |
| Hoya 7741.T | $47.4B | -23% | +13% | 31% | 26.7× | 13.3% |
| Menicon 7780.T | $854M | +12% | +5% | 9% | 19.3× | n/a |
| Santen Pharmaceutical 4536.T | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLCO.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.8% | +9.1% | 6th highest of 21 |
| 6-month return | +31.1% | +27.7% | 10th highest of 21 |
| Distance from 52-week high | -5.2% | -9.6% | 7th highest of 21 |
| Revenue growth (TTM) | +11.3% | +2.7% | 6th highest of 21 |
| Operating margin | 9.4% | 17.3% | 4th lowest of 21 |
| Forward P/E | 17.3× | 21.0× | 4th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 11.0% | 10.3% | 9th most demanding of 20 |
| Growth delivered (Del g) | +10.0% | +9.5% | 10th highest of 20 |
| Hurdle (Req g minus delivered) | +0.9 pp | -1.1 pp | 10th most demanding of 20 |
| ROIC minus cost of capital | -2.9 pp | +2.8 pp | 5th lowest of 21 |
| EV / EBITDA | 12.8× | 15.6× | 5th cheapest of 18 |
| Net debt / EBITDA | 5.0× | 0.9× | 2nd most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 13% | 29.4× | 24.1% | +9.3% |
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% | +35.3% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| Globus Medical GMED | United States | $9.54B | -9% | +20% | 22% | 14.1× | 5.5% | +30.1% |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| Insulet PODD | United States | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% | +24.5% |
| Bio-Rad Laboratories BIO | United States | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% | +0.3% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| Qiagen QGEN | United States | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% | +2.2% |